Natural GLP-1 alternatives: Whos the target market
That narrow scope is really the only caveat, and it doubles as the selling point: the deep citation record and recombinant expertise are why rPeptide ranks among the best peptide companies for neurodegeneration research
Reference: 3D cell-printing of gradient multi-tissue interfaces for rotator cuff regeneration by Suhun Chae, Uijung Yong, Wonbin Park, Yoo-mi Choi, In-Ho Jeon, Homan Kang, Jinah Jang, Hak Soo Choi and Dong-Woo Cho, 11 May 2022, Bioactive Materials
& Luthman, H
It specifically names patients with prediabetes, early insulin resistance, or a BMI in the 25 to 29 range as candidates who may benefit from structured lifestyle intervention before pharmaceutical escalation
It is similar enough to GLP-1 to allow it to fit into the GLP-1 receptor and act as an agonist